Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. (APGE) priced its initial public offering on Jul 17, 2023 at $17.00 per share, within its $15.00–$17.00 range, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $809.5M. Jefferies was lead-left underwriter, joined by TD Cowen, Stifel and Guggenheim and others. Gibson Dunn advised the company and Cooley advised the underwriters.

Apogee Therapeutics, Inc. is a biotechnology company developing differentiated antibody biologics for atopic dermatitis, chronic obstructive pulmonary disease and related inflammatory and immunology indications. Its most advanced programs are APG777 for atopic dermatitis and APG808 for COPD.

Status

IPO

Ticker

APGE

Exchange

Nasdaq Global Market

Priced

Jul 17, 2023

IPO price

$17.00

Price range

$15.00–$17.00

Market cap at IPO price

$809.5M

First filed

Jun 22, 2023

Underwriters

Jefferies, TD Cowen, Stifel, Guggenheim and Wedbush

Company counsel

Gibson Dunn

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.